Characterisation of different nanoparticles with a potential use for drug delivery in neuropsychiatric disorders.
Nanoparticles are promising tools for targeted delivery of drugs in the treatment of different diseases, including neuropsychiatric disorders. However, they need to be carefully characterised for any adverse effects which may occur in their presence. In this study, we evaluated the applicability of nanoparticles that belong to three different groups: (i) aggregates from amphiphilic diblock copolymers composed of poly(2-ethyl-2-oxazoline) (PEtOx) and poly(2-phenyl-2-oxazoline) (PPhOx) in different ratios, (ii) stabilised polymeric micelles (SPM) based on poly(ethylene oxide)-b-poly(propylene oxide)-bpoly(ethylene oxide) (PEO-PPO-PEO) and (iii) star-like polymer with poly(acrylic acid) arms and branched polystyrene interior (PSPAA). Using cultured human neural progenitor cells, we characterised six nanoparticles (POx-9, POx-23 and POx-46 - the polyoxazoline group, SPM-F38 and SPMMS - the SPM group, and PSPAA - the star-like polymer) for neurotoxicity and effect on neurodevelopmental genes. Nanoparticles ability to activate complement system in blood was assessed by ELISA. None of the nanoparticles exhibited neurotoxicity. However, POx-9, POx-23, POx-46 and SPM-F38 activated complement system. POx-9 and SPM-F38 resulted in inhibition of expression of 19 and 26 out of 30 tested neurodevelopmental genes, respectively. Considering the properties of the studied nanoparticles, only PSPAA and SPMMS can be used at high concentrations for drug delivery without compromising neurogenesis and neurodevelopment, and activation of complement system.